Journal of thoracic disease · 2025
Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jing, Pang Boyue, Zhang Jiali, Ren Xiubao, Han Ying
Аннотация
BACKGROUND: Malignant pleural effusion (MPE) is a common metastatic site in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. However, data on MPE in the context of immunotherapy are limited. This study aimed to evaluate the clinical outcomes of NSCLC patients with MPE undergoing immunotherapy.
METHODS: This study included NSCLC patients treated with immune checkpoint inhibitors (ICIs) at Tianjin Medical University Cancer Institute & Hospital from January 2018 to August 2024. The presence of cytologically confirmed MPE was defined as the MPE group, against which the absence of pleural effusion was defined as the control group. The primary endpoints were overall survival (OS) and progression-free survival (PFS).
RESULTS: A total of 167 NSCLC patients treated with ICIs were included, with 84 in the MPE group and 83 in the control group. There were statistically significant differences in PFS and OS between the MPE and control groups (both P<0.05). The median follow-up was 18 months. The median PFS in the MPE group was 9.50 months [95% confidence interval (CI): 7.08-11.92], while in the control group, the median PFS was 16.50 months (95% CI: 8.74-24.26). The median OS in the MPE group was 20.0 months (95% CI: 15.61-24.39), while in the control group, the median OS was 32.0 months (95% CI: 18.11-45.89).
CONCLUSIONS: MPE remains an independent risk factor for poor prognosis in NSCLC even after immunotherapy.
METHODS: This study included NSCLC patients treated with immune checkpoint inhibitors (ICIs) at Tianjin Medical University Cancer Institute & Hospital from January 2018 to August 2024. The presence of cytologically confirmed MPE was defined as the MPE group, against which the absence of pleural effusion was defined as the control group. The primary endpoints were overall survival (OS) and progression-free survival (PFS).
RESULTS: A total of 167 NSCLC patients treated with ICIs were included, with 84 in the MPE group and 83 in the control group. There were statistically significant differences in PFS and OS between the MPE and control groups (both P<0.05). The median follow-up was 18 months. The median PFS in the MPE group was 9.50 months [95% confidence interval (CI): 7.08-11.92], while in the control group, the median PFS was 16.50 months (95% CI: 8.74-24.26). The median OS in the MPE group was 20.0 months (95% CI: 15.61-24.39), while in the control group, the median OS was 32.0 months (95% CI: 18.11-45.89).
CONCLUSIONS: MPE remains an independent risk factor for poor prognosis in NSCLC even after immunotherapy.